Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trilaciclib with concurrent chemoradiotherapy followed by envafolimab consolidation in limited-stage small-cell lung cancer
ChiCTR2600125546Phase 2Not yet recruiting
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Start
- May 2026
- Modality
- Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of trilaciclib and envafolimab in small cell lung cancer (SCLC), sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Primary endpoints: Progression-free survival (PFS), Incidence of adverse events and serious adverse events and 1 more. Planned start May 2026; status: not yet recruiting.
02
Drugs
trilaciclibenvafolimab
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on ChiCTR2600125546.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600125546.